2025/04/01

CIC bioGUNE receives the Development and Innovation Management team from FAES Farma

CIC bioGUNE, member of BRTA, has had the honor of receiving today the Management team of Development and Innovation of FAES Farma, one of the main pharmaceutical companies in Bizkaia, specialized in drug research and development. The delegation visiting CIC bioGUNE was composed of José Luis Velada, Director of Research and Development, and Tatiana Suárez, Head of Research, Development and Innovation. During their tour, they were able to gain a detailed understanding of the facilities and the most significant projects currently being developed at the center.

FAES Farma, based in Leioa (Bizkaia), has more than 85 years of experience in the pharmaceutical sector and is recognized for its firm commitment to scientific innovation and the development of advanced therapeutic solutions. Specializing in key areas such as neuroscience, respiratory and digestive health, the company is committed to researching treatments that improve the quality of life of patients globally. Its focus on the creation of new medicines is supported by a solid infrastructure and a team of highly qualified professionals working to respond to the most urgent health needs.

During their visit to CIC bioGUNE, the FAES Farma delegation had the opportunity to see not only the facilities of the center, but also the most innovative scientific projects in which substantial advances in biomedicine, biotechnology and personalized therapies are being achieved. FAES Farma representatives were able to delve into the lines of research that CIC bioGUNE is carrying out, highlighting the collaboration between the two entities as key to the advancement of new therapeutic solutions.

This visit not only reaffirms CIC bioGUNE's commitment to cutting-edge research but also highlights the importance of strengthening collaboration between the academic sector and the pharmaceutical industry. In doing so, it seeks to accelerate knowledge transfer and innovation, which will open up new opportunities in the field of biomedicine. It also underlines the role of Bizkaia as a pole of innovation and knowledge, consolidating itself as a reference in the scientific and biotechnological field.

About FAES Farma

FAES Farma is a Basque pharmaceutical company with more than 85 years of experience, dedicated to the research, development, production and marketing of products in various therapeutic areas. Founded in 1933, it has a solid track record in the creation of innovative pharmacological solutions, committed to health and scientific progress, and with a vision of the future focused on the continuous improvement of its products and services.

About CIC bioGUNE

The Centre for Cooperative Research in Biosciences (CIC bioGUNE), member of the Basque Research & Technology Alliance (BRTA), located in the Bizkaia Technology Park, is a biomedical research organization conducting cutting-edge research at the interface between structural, chemical, molecular and cell biology, with a particular focus on generating knowledge on the molecular bases of disease, for use in the development of new diagnostic methods and advanced therapies.

About BRTA

BRTA is an alliance of 4 collaborative research centres (CIC bioGUNE, CIC nanoGUNE, CIC biomaGUNE y CIC energiGUNE) and 13 technology centres (Azterlan, Azti, Ceit, Cidetec, Gaiker, Ideko, Ikerlan, Leartiker, Lortek, Neiker, Tecnalia, Tekniker y Vicomtech) with the main objective of developing advanced technological solutions for the Basque corporate fabric.

With the support of the Basque Government, the SPRI Group and the Provincial Councils of the three territories, the alliance seeks to promote collaboration between the research centres, strengthen the conditions to generate and transfer knowledge to companies, contributing to their competitiveness and outspreading the Basque scientific-technological capacity abroad.

BRTA has a workforce of over 4,000 professionals, executes 22% of the Basque Country's R&D investment, registers an annual turnover of more than 300 million euros and generates 100 European and international patents per year.

Spanish version